Rhythm Pharmaceuticals on the Verge of Approval for its HO drug – Billion-Dollar Market Without Serious Competition

Rhythm Pharmaceuticals is on the verge of the first approval for rare hypothalamic obesity – a billion-dollar market with little competition. Oral and weekly variants in the pipeline ensure long-term market shares and growth potential. Rhythm Pharmaceuticals (NASDAQ: RYTM) is purposefully advancing into a field that is barely recognized by the general public but holds enormous potential for the company: the treatment of rare, hypothalamic or genetically induced forms of obesity. The current flagship is the MC4R agonist Setmelanotide,...